Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. BioArctic AB (publ)
  6. Summary
    BIOA B   SE0010323311

BIOARCTIC AB (PUBL)

(BIOA B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 12/02 08:36:12 am
114.9 SEK   -4.57%
11/15BioArctic Develops New Antibody Treatment for ALS
CI
11/15BioArctic develops new antibody treatment for ALS
AQ
11/15New data on lecanemab presented at the CTAD Alzheimer conference
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
118.2(c) 119.6(c) 120.4(c) 120.4(c) 115.2 Last
188 971 148 630 156 561 200 970 74 073 Volume
-1.50% +1.18% +0.67% 0.00% -4.32% Change
More quotes
Estimated financial data (e)
Sales 2021 159 M 17,6 M 17,6 M
Net income 2021 -60,3 M -6,66 M -6,66 M
Net cash position 2021 904 M 99,8 M 99,8 M
P/E ratio 2021 -176x
Yield 2021 -
Sales 2022 411 M 45,3 M 45,3 M
Net income 2022 279 M 30,8 M 30,8 M
Net cash position 2022 1 165 M 129 M 129 M
P/E ratio 2022 38,2x
Yield 2022 -
Capitalization 10 602 M 1 174 M 1 171 M
EV / Sales 2021 60,9x
EV / Sales 2022 23,0x
Nbr of Employees 49
Free-Float 40,2%
More Financials
Company
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform,... 
Sector
Biotechnology & Medical Research
Calendar
02/03 | 02:00amEarnings Release
More about the company
Ratings of BioArctic AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about BIOARCTIC AB (PUBL)
11/15BioArctic Develops New Antibody Treatment for ALS
CI
11/15BioArctic develops new antibody treatment for ALS
AQ
11/15New data on lecanemab presented at the CTAD Alzheimer conference
AQ
11/08DIAN-TU selects lecanemab for clinical trial for dominantly inherited Alzheimer's disea..
AQ
11/08Bioarctic AB Announces DIAN-TU Selects Lecanemab for Clinical Trial for Dominantly Inhe..
CI
11/08New data published on ABBV-0805 in Neurobiology of Disease
AQ
11/08Bioarctic AB Announces New Data Published on Abbv-0805 in Neurobiology of Disease
CI
11/04New data on lecanemab to be presented at the 14 Clinical Trials on Alzheimer's Disease ..
AQ
11/01BioArctic presents Nomination Committee
AQ
11/01BioArctic AB Presents Nomination Committee
CI
10/21BIOARCTIC : Interim Report for the period July – September 2021
PU
10/21BIOARCTIC : Interim Report for the period July - September 2021
AQ
10/21BioArctic AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
10/11BIOARCTIC : Invitation to presentation of BioArctic's Interim Report for the period Januar..
PU
10/11BIOARCTIC : Invitation to presentation of BioArctic's Interim Report for the period Januar..
AQ
More news
News in other languages on BIOARCTIC AB (PUBL)
2020BIOARCTIC AB (PUBL) : secoué par Biogen
2019BIOARCTIC AB : BAN2401 bientôt en phase III
2018HBM erzielt Gewinnsprung im ersten Halbjahr 2018 - Zuversichtlich für Gesamtjahr
2017BIOGEN : échec d'étude dans la maladie d'Alzheimer
More news
Chart BIOARCTIC AB (PUBL)
Duration : Period :
BioArctic AB (publ) Technical Analysis Chart | BIOA B | SE0010323311 | MarketScreener
Technical analysis trends BIOARCTIC AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 120,40 SEK
Average target price 227,67 SEK
Spread / Average Target 89,1%
EPS Revisions
Managers and Directors
Gunilla Christina Osswald President & Chief Executive Officer
Jan P. Mattsson Chief Financial Officer & Vice President-Finance
Wenche Nelly A. Rolfsen Sandsborg Chairman
Christer M÷ller Chief Scientific Officer
Tomas Odergren Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOARCTIC AB (PUBL)26.21%1 174
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625